Non-alcoholic fatty liver disease historical perspective: Difference between revisions

Jump to navigation Jump to search
 
(12 intermediate revisions by 2 users not shown)
Line 4: Line 4:
   
   
==Overview==
==Overview==
NAFLD/NASH was first described in a 1980 series of [[obese]], non-alcoholic patients of the [[Mayo Clinic]].<ref>Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.</ref> Since that seminal description, our understanding of [[NAFLD]] has progressed minimally. <ref>Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.</ref>
Ludwig was the first physician to describe the non-alcoholic fatty liver disease as a separate medical entity from other fatty liver diseases.


==Historical Perspective==
==Historical Perspective==


*First introduced in 1980, NAFLD is a quite new concept. <ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref>
*In 1980, Ludwig was the first physician to describe non-alcoholic fatty liver disease as a separate medical entity from other fatty liver diseases.<ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref name="pmid285079292">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref name="pmid7382552">{{cite journal |vauthors=Ludwig J, Viggiano TR, McGill DB, Oh BJ |title=Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease |journal=Mayo Clin. Proc. |volume=55 |issue=7 |pages=434–8 |year=1980 |pmid=7382552 |doi= |url=}}</ref>
*It is divided into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) primarily based on histologic findings.
*In 1983, Adler & Schaffner described the association between obesity and  non-alcoholic fatty liver disease.
*Biopsies of NAFL may also display macrovesicular steatosis with lobular and periportal irritation however do now not display cellular injury and fibrosis (steatohepatitis), which characterizes NASH. <ref name="pmid28297791">{{cite journal |vauthors=Zhao ZH, Liu XL, Fan JG |title=[Research on the natural history of non-alcoholic fatty liver disease should be taken seriously] |language=Chinese |journal=Zhonghua Gan Zang Bing Za Zhi |volume=25 |issue=2 |pages=81–84 |year=2017 |pmid=28297791 |doi= |url=}}</ref>
*In 1984, Andersen & Gluud conducted numerous experiments with extensive documentation of the liver biopsies in patients with non-alcoholic fatty liver disease.
*NAFL has in large part been taken into consideration benign, but recent cohort studies display a high hazard for development to NASH in as much as 44% on serial biopsies at 5 years.
*In 1985, Bockus was the first to coin the term non-alcoholic fatty liver.
*NASH reasons modern fibrosis which could result in cirrhosis and hepatocellular cancer (HCC).


==References==
==References==

Latest revision as of 00:34, 28 December 2017

Non-Alcoholic Fatty Liver Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Non-alcoholic fatty liver disease historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-alcoholic fatty liver disease historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-alcoholic fatty liver disease historical perspective

CDC on Non-alcoholic fatty liver disease historical perspective

Non-alcoholic fatty liver disease historical perspective in the news

Blogs on Non-alcoholic fatty liver disease historical perspective

Directions to Hospitals Treating Non-alcoholic fatty liver disease

Risk calculators and risk factors for Non-alcoholic fatty liver disease historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Ludwig was the first physician to describe the non-alcoholic fatty liver disease as a separate medical entity from other fatty liver diseases.

Historical Perspective

  • In 1980, Ludwig was the first physician to describe non-alcoholic fatty liver disease as a separate medical entity from other fatty liver diseases.[1][2][3]
  • In 1983, Adler & Schaffner described the association between obesity and non-alcoholic fatty liver disease.
  • In 1984, Andersen & Gluud conducted numerous experiments with extensive documentation of the liver biopsies in patients with non-alcoholic fatty liver disease.
  • In 1985, Bockus was the first to coin the term non-alcoholic fatty liver.

References

  1. Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
  2. Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
  3. Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980). "Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease". Mayo Clin. Proc. 55 (7): 434–8. PMID 7382552.

Template:WS Template:WH